Publications by authors named "Chung-Pin Li"

The stimulator of interferon genes (STING) pathway is crucial for tumor immunity, leading to the exploration of STING agonists as potential immunotherapy adjuvants. However, their clinical application faces obstacles including poor pharmacokinetics, transient activation, and an immunosuppressive tumor microenvironment (TME). Addressing these limitations, our study aims to develop an injectable silk fibroin hydrogel-based in situ vaccine.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates using entrustable professional activities (EPAs) as an alternative to the traditional objective structured clinical examination (OSCE) for medical students during their rotations.
  • Involving 265 students, the research assessed their performance on 13 EPAs and analyzed the correlation between EPA results and OSCE scores, finding that most EPAs were significantly linked to OSCE performance.
  • Results indicate that EPAs may effectively predict OSCE success, suggesting they could serve as a viable substitute for OSCE assessments in evaluating medical student competencies.
View Article and Find Full Text PDF

Background: Surgical resection (SR) is the main treatment for small bowel adenocarcinoma (SBA), but it increases metabolic demand, systemic inflammation, and digestive dysfunction, resulting in major impacts on the postoperative outcomes of patients. In this study, we aimed to investigate the role of the postoperative prognostic nutritional index (PNI), a surrogate marker of inflammation and nutrition, in patients with SBA after resection.

Methods: From June 2014 to March 2022, 44 consecutive patients who underwent SR for SBA in Taipei Veterans General Hospital were retrospectively reviewed.

View Article and Find Full Text PDF

Background: Despite the known association between microorganisms and development of inflammatory bowel disease (IBD), the role of nontyphoidal Salmonella (NTS) in IBD is not adequately addressed. We aimed at elucidating the relationship between NTS infection and the risk of IBD.

Methods: Based on the National Health Insurance Research Database in Taiwan, this retrospective cohort study enrolled patients with NTS infection (exposure group; n = 4651) and those without NTS infection (comparator group; n = 4651) who were propensity score matched (1:1) by demographic data, medications, comorbidities, and index date.

View Article and Find Full Text PDF

Background/objectives: Liposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI + 5-FU/LV) provides survival benefits for metastatic pancreatic adenocarcinoma (mPDAC) refractory to gemcitabine-based treatment, mainly gemcitabine plus nab-paclitaxel (GA), in current practice. Gemcitabine plus S-1 (GS) is another commonly administered first-line regimen before nab-paclitaxel reimbursement; however, the efficacy and safety of nal-IRI + 5-FU/LV for mPDAC after failed GS treatment has not been reported and was therefore explored in this study.

Methods: In total, 177 patients with mPDAC received first-line GS or GA treatment, followed by second-line nal-IRI + 5-FU/LV treatment (identified from a multicenter retrospective cohort in Taiwan from 2018 to 2020); 85 and 92 patients were allocated to the GS and GA groups, respectively.

View Article and Find Full Text PDF

Detecting pancreatic duct adenocarcinoma (PDAC) in its early stages and predicting late-stage patient prognosis undergoing chemotherapy is challenging. This work shows that the activation of specific oncogenes leads to elevated expression of mRNAs and their corresponding proteins in extracellular vesicles (EVs) circulating in blood. Utilizing an immune lipoplex nanoparticle (ILN) biochip assay, these findings demonstrate that glypican 1 (GPC1) mRNA expression in the exosomes-rich (Exo) EV subpopulation and GPC1 membrane protein (mProtein) expression in the microvesicles-rich (MV) EV subpopulation, particularly the tumor associated microvesicles (tMV), served as a viable biomarker for PDAC.

View Article and Find Full Text PDF

Pancreatic cancer is a highly aggressive malignancy with a poor prognosis. Over the past decade, significant therapeutic advancements have improved the survival rates of patients with pancreatic cancer. One of the primary factors contributing to these positive outcomes is the evolution of chemotherapy, from monotherapy to doublet or triplet regimens, and the integration of multimodal approaches.

View Article and Find Full Text PDF

Purpose: Coronavirus disease 2019 (COVID-19) has heavily impacted medical clinical education in Taiwan. Medical curricula have been altered to minimize exposure and limit transmission. This study investigated the effect of COVID-19 on Taiwanese medical students' clinical performance using online standardized evaluation systems and explored the factors influencing medical education during the pandemic.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigated the safety and effectiveness of abemaciclib, both alone and in combination with other treatments, for patients with previously treated metastatic pancreatic ductal adenocarcinomas (PDAC).
  • The trial compared abemaciclib to standard chemotherapy and found that it did not provide significant improvements in disease control rates (DCR) or progression-free survival (PFS).
  • Ultimately, no treatment combinations moved to the next phase of testing, confirming that abemaciclib is still considered investigational for this type of cancer.
View Article and Find Full Text PDF

Purpose: The predictive value of carbohydrate antigen 19-9 (CA19-9) for adjuvant chemo(radiation) therapy of resected pancreatic adenocarcinoma (PDAC) is undefined.

Methods And Materials: We analyzed CA19-9 levels in patients with resected PDAC in a prospective randomized trial of adjuvant chemotherapy with or without additional chemoradiation therapy (CRT). Patients with postoperative CA19-9 ≤92.

View Article and Find Full Text PDF

Background: Compared with normal cells, tumour cells contain elevated levels of reactive oxygen species (ROS). Increased levels of the antioxidant protein NAD(P)H:quinone oxidoreductase 1 (NQO1) and phosphorylated signal transducer and activator of transcription 3 (pSTAT3) correlate negatively with the survival of patients with pancreatic cancer. Napabucasin is an investigational, orally administered ROS generator bioactivated by NQO1.

View Article and Find Full Text PDF

Background: The nomogram derived from the pivotal phase III NAPOLI-1 study demonstrated a significant ability to predict median overall survival (OS) in gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) treated with liposomal irinotecan plus fluorouracil and leucovorin (nal-IRI+5-FU/LV). However, the NAPOLI-1 nomogram has not been validated in a real-world setting and therefore the applicability of the NAPOLI-1 nomogram in daily practice remains unknown. This study aims to evaluate the NAPOLI-1 nomogram in a multicenter real-world cohort.

View Article and Find Full Text PDF

Purpose: This randomized, open-label trial compared the efficacy and safety of adjuvant -paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430).

Methods: We assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to -paclitaxel (125 mg/m) + gemcitabine (1,000 mg/m) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles.

View Article and Find Full Text PDF
Article Synopsis
  • Liposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin shows improved survival for pancreatic ductal adenocarcinoma (PDAC) patients after they progress from gemcitabine therapy.
  • A study of 667 patients analyzed the effects of starting doses and escalation of nal-IRI on survival and toxicity, categorizing them into standard and reduced doses with or without escalation.
  • Results indicated that patients with reduced doses followed by escalation had the longest treatment cycles and better overall survival compared to those on standard doses or reduced doses without escalation, although standard doses resulted in higher rates of severe side effects.
View Article and Find Full Text PDF

There are no data comparing the efficacy and safety of prophylactic entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) for HBV-infected cancer patients undergoing chemotherapy. This study aimed to compare the efficacy and renal safety of ETV, TDF and TAF in this setting. HBsAg-positive cancer patients treated with ETV (n = 582), TDF (n = 200) and TAF (n = 188) during chemotherapy were retrospectively enrolled.

View Article and Find Full Text PDF
Article Synopsis
  • Liposomal irinotecan combined with 5-fluorouracil and leucovorin shows survival benefits in pancreatic ductal adenocarcinoma (PDAC) but also presents side effects, especially in patients resistant to gemcitabine.
  • The study examined the albumin and neutrophil-to-lymphocyte ratio score (ANS) as a tool to predict survival and safety in 434 PDAC patients treated with nal-IRI + 5-FU/LV.
  • Results indicated that higher ANS scores correlated with worse survival rates and increased treatment-related adverse events, confirming ANS as a significant predictor of outcomes in these patients.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the effectiveness of a specific chemotherapy regimen (GSL) in elderly patients (age ≥70) with advanced pancreatic adenocarcinoma (APC), as this group previously faced challenges in receiving treatment and had lower survival rates.
  • Of 49 enrolled patients, those who underwent GSL treatment showed a median progression-free survival of 6.6 months and an overall survival of 12.5 months, with 26.5% achieving an overall response to treatment.
  • The treatment was relatively well tolerated, with some notable side effects like anemia and neutropenia, and resulted in improved emotional and health status for the patients, paving the way for further studies on the
View Article and Find Full Text PDF

Purpose: In 2013, medical schools in Taiwan implemented a 6-year medical program that replaced the previous 7-year medical education program. The postgraduate year (PGY) program was also extended from 1 year to 2 years. The new program is characterized by diversified teaching, integration of medical skills, a system-oriented curriculum, and the implementation of primary care and clinical thinking training.

View Article and Find Full Text PDF
Article Synopsis
  • A multicenter study was conducted to assess how the cumulative dose and dosing patterns of liposomal irinotecan plus fluorouracil/leucovorin (nal-IRI+5-FU/LV) affect survival in patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • The study reviewed medical records of 473 patients, finding that higher cumulative doses of the treatment led to significantly longer median overall survival (mOS), with those receiving >80% of the dose surviving the longest.
  • The findings indicate that starting treatment with a lower dose followed by potential dose increases can achieve survival rates similar to a standard dose approach, highlighting the effectiveness of nal-IRI+5-F
View Article and Find Full Text PDF

Objectives: Self-expandable metallic stent (SEMS) placement is a safe and effective palliative treatment for malignant gastric outlet obstruction; however, the clinical outcomes of gastric and duodenal stenoses may differ. This study aimed to investigate the clinical efficacy of SEMS placement and the predictors of clinical outcomes, specifically in malignant duodenal obstruction (MDO).

Methods: Between September 2009 and March 2021, 79 patients with MDO who received SEMS placement in our hospital were retrospectively enrolled.

View Article and Find Full Text PDF

Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (NalFL) comprises the current standard for gemcitabine-failed metastatic pancreatic ductal adenocarcinoma (PDAC). As liposomes generally accumulate in the spleen, we evaluated the impact of spleen volume on prognosis. We enrolled patients with metastatic PDAC who failed gemcitabine-based therapy and were initiated on NalFL between August 2018 and November 2020.

View Article and Find Full Text PDF

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive and has poor prognosis. There are few biomarkers to inform treatment decisions, and collecting tumour samples for testing is challenging.

Methods: Circulating tumour cells (CTCs) from patients with PDAC liquid biopsies were expanded ex vivo to form CTC-derived organoid cultures, using a laboratory-developed biomimetic cell culture system.

View Article and Find Full Text PDF

Background: Recent studies have suggested the suboptimal efficacy of liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients previously treated with conventional irinotecan. This study investigated the effect of conventional irinotecan treatment in mPDAC patients receiving nal-IRI+5-FU/LV by analyzing a population-based dataset.

Methods: We reviewed 667 consecutive mPDAC patients treated with nal-IRI+5-FU/LV between August 2018 and November 2020 at Taiwanese medical centers.

View Article and Find Full Text PDF